Strong Q1 operating profit hides weaker revenues at new-look Novartis
This article was originally published in Scrip
Swiss major Novartis missed its consensus revenues estimates but nonetheless posted a very healthy operating profit in the first quarter thanks largely to higher margins in its pharma and Sandoz divisions.
You may also be interested in...
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.